The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus: a systematic review and meta-analysis of clinical trials.
Beraprost sodium
Cardiometabolic
Diabetes mellitus
Meta-analysis
Renal function
Systematic review
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
18
10
2020
accepted:
08
05
2021
pubmed:
22
5
2021
medline:
25
2
2022
entrez:
21
5
2021
Statut:
ppublish
Résumé
This systematic review and meta-analysis aimed to assess renal function and cardiometabolic biomarkers after treatment with beraprost sodium in patients with diabetes mellitus. We systemically searched PubMed, Embase, Scopus, Web of Science, and Cochrane Library up to August 2020. Statistical heterogeneities were computed using Cochrane's Q test and I From 341citations, seven trials were included into our meta-analysis. Our findings demonstrated that beraprost sodium intake significantly decreased blood urea nitrogen (BUN) (WMD = -5.62, 95% CI [-8.49, -2.74], P < 0.001) and cystatin C (WMD = -0.57, 95% CI [-0.68, -0.46], P < 0.001). Beraprost sodium intake had no significant effect on fasting blood sugar (FBS), hemoglobin A1c (HbA1c), cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, systolic blood pressure (SBP), diastolic blood pressure (DBP), and creatinine (Cr) in patients with diabetes receiving beraprost sodium in comparison with the controls. Our meta-analysis revealed that beraprost sodium administration significantly decreased BUN and cystatin C levels in patients with diabetes. However, no significant effect was observed on the cardiometabolic profile.
Identifiants
pubmed: 34019221
doi: 10.1007/s11255-021-02887-7
pii: 10.1007/s11255-021-02887-7
doi:
Substances chimiques
Biomarkers
0
beraprost
35E3NJJ4O6
Epoprostenol
DCR9Z582X0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-120Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Alrawahi AH, Rizvi SG, Al-Riyami D, Al-Anqoodi Z (2012) Prevalence and risk factors of diabetic nephropathy in omani type 2 diabetics in Al-dakhiliyah region. Oman Med J 27(3):212–216
doi: 10.5001/omj.2012.48
Kim M, Kim JU, Kim SM, Kim H (2017) Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis. Int Urol Nephrol 49(7):1287–1295
doi: 10.1007/s11255-017-1586-y
Magee C, Grieve DJ, Watson CJ, Brazil DP (2017) diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther 31(5–6):579–592
doi: 10.1007/s10557-017-6755-9
Lièvre M, Morand S, Besse B, Fiessinger JN, Boissel JP (2000) Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 102(4):426–431
doi: 10.1161/01.CIR.102.4.426
Guan J, Long L, Chen YQ, Yin Y, Li L, Zhang CX et al (2014) Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy. GMR 13(2):4154–4158
doi: 10.4238/2014.June.9.1
Li S, Wang Y, Chen L, Wang Z, Liu G, Zuo B et al (2019) Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berl) 97(6):777–791
doi: 10.1007/s00109-019-01769-x
Choi YM, Kwon HS, Choi KM, Lee WY, Hong EG (2019) Short-term effects of beraprost sodium on the markers for cardiovascular risk prediction in type 2 diabetic patients with microalbuminuria. Endocrinol Metab 34(4):398–405
doi: 10.3803/EnM.2019.34.4.398
Xu X, Pan X, Li S (2020) Prospective analysis of the efficacy of beraprost sodium combined with alprostadil on diabetic nephropathy and influence on rennin-angiotensin system and TNF-α. Exp Ther Med 19(1):639–645
pubmed: 31885702
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
doi: 10.1371/journal.pmed.1000097
Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions, version 5.1. 0
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558
doi: 10.1002/sim.1186
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
doi: 10.1136/bmj.315.7109.629
Owada A, Suda S, Hata T (2002) Effect of long-term administration of prostaglandin I(2) in incipient diabetic nephropathy. Nephron 92(4):788–796
doi: 10.1159/000065445
Goya K, Otsuki M, Xu X, Kasayama S (2003) Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 52(2):192–198
doi: 10.1053/meta.2003.50025
Shin S, Kim KJ, Chang HJ, Lee BW, Yang WI, Cha BS et al (2012) The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial. Diabetes Obes Metab 15(2):185–188
doi: 10.1111/dom.12010
Shima A, Miyamoto M, Kubota Y, Takagi G, Shimizu W (2015) Beraprost sodium protects against diabetic nephropathy in patients with arteriosclerosis obliterans: a prospective, randomized, open-label study. J Nippon Med Sch 82(2):84–91
doi: 10.1272/jnms.82.84
Xia J, Shen S (2019) Efficacy of beraprost sodium in the treatment of diabetic nephropathy in elderly patients. Int J Clin Exp Med 12(5):5927–5932
Barbieri SS, Amadio P, Gianellini S, Tarantino E, Zacchi E, Veglia F et al (2012) Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner. Circulation 126(11):1373–1384
doi: 10.1161/CIRCULATIONAHA.112.097295
Vizza CD, Sciomer S, Morelli S, Lavalle C, Di Marzio P, Padovani D et al (2001) Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 86(6):661–665
doi: 10.1136/heart.86.6.661
Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH et al (2012) Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e669S – e690
doi: 10.1378/chest.11-2307
Palatini P (2012) Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 27(5):1708–1714
doi: 10.1093/ndt/gfs037